Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that micro-needling with triamcinolone acetonide led to the best treatment outcomes for alopecia areata compared to other methods of trans-epidermal drug delivery.

This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.

This case report suggests that platelet-rich plasma injections may offer a new and potentially effective treatment for alopecia areata barbae, as demonstrated by notable hair regrowth in one patient over one year.

In this study, a 21-year-old male with alopecia areata showed complete hair regrowth after following a 100-day holistic Ayurveda treatment, which included Pracchana karma, Gunja-Kalihari lepa application, and Ayurveda formulations, resulting in a SALT-2 score reduction from 66% to 0%.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This study reports that topical pumpkin seed oil and sesame oil were both effective in treating alopecia areata, with no significant difference in effectiveness between the two after three months.

This commentary discusses the cultural and biological significance of hair, intertwined with humorous and poignant anecdotes from cancer care, and reports no new research findings.

PRP therapy at Ethos Spa improves hair growth and quality with minimal maintenance.

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.

This study observed that testosterone inhibits hair follicle epithelial cell proliferation in adult stumptailed macaques only when dermal papilla cells from bald scalps are present, with antiandrogen RU 58841 reversing this effect.

This study suggests that autologous fat transfer can significantly enhance hair growth in patients with scarring alopecia, offering more consistent and predictable results when combined with hair transplantation.

This study examined five patients with cicatricial alopecia treated using the follicular unit extraction technique, finding an average graft survival rate of 64.2% and acceptable transection rates, despite the procedure's challenges compared to non-scarring alopecia.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

This narrative review discusses the potential of urinary bladder matrix as a bio-scaffold in hair restoration but provides no new clinical results or trials; it highlights regenerative technology and suggests further exploration.

This article reviews CRISPR/Cas system delivery methods for genome editing and highlights RNA's promise in non-viral in vivo applications but reports no new clinical results.

This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.

This article reviews previously reported cases of whisker hair in individuals who develop severe androgenic alopecia and offers a hypothesis concerning its eventual fate, without presenting new findings.

This case series reported that patients with trichotillomania and pseudofolliculitis experienced improvement in itch symptoms and hair regrowth after receiving topical steroids, topical, or oral antibiotics.

In this study, baricitinib was effective in improving hair regrowth in patients with severe alopecia areata over one year, especially when treatment began within four years of symptom onset.

This study reported that 57.4% of children under 10 with early-onset alopecia areata experienced over 50% hair regrowth after treatment with topical corticosteroids, noting that those under 4 showed significantly better responses, although personal atopic history was the only differing prognostic factor.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

UV dermoscopy helps detect white hairs in children more effectively.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This case study reports that platelet-rich plasma treatment led to total hair regrowth in a 71-year-old woman with alopecia areata who had not responded to previous standard therapies.

This review discusses prevention, diagnosis, and treatment strategies for traction alopecia but presents no new clinical findings; the authors emphasize early intervention to prevent permanent hair loss.

This article poses the question of whether Janus kinase (JAK) inhibitors are beneficial for treating androgenic alopecia, but it does not provide results or conclusions from any study.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.